These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 15217351)
1. Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site. Venäläinen JI; Juvonen RO; Garcia-Horsman JA; Wallén EA; Christiaans JA; Jarho EM; Gynther J; Männistö PT Biochem J; 2004 Sep; 382(Pt 3):1003-8. PubMed ID: 15217351 [TBL] [Abstract][Full Text] [Related]
2. Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. Venäläinen JI; Garcia-Horsman JA; Forsberg MM; Jalkanen A; Wallén EA; Jarho EM; Christiaans JA; Gynther J; Männistö PT Biochem Pharmacol; 2006 Feb; 71(5):683-92. PubMed ID: 16405869 [TBL] [Abstract][Full Text] [Related]
3. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions. Jarho EM; Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J; Poso A J Med Chem; 2005 Jul; 48(15):4772-82. PubMed ID: 16033257 [TBL] [Abstract][Full Text] [Related]
4. Prolyl oligopeptidase inhibition by N-acyl-pro-pyrrolidine-type molecules. Kánai K; Arányi P; Böcskei Z; Ferenczy G; Harmat V; Simon K; Bátori S; Náray-Szabo G; Hermecz I J Med Chem; 2008 Dec; 51(23):7514-22. PubMed ID: 19006380 [TBL] [Abstract][Full Text] [Related]
5. New prolyl oligopeptidase inhibitors developed from dicarboxylic acid bis(l-prolyl-pyrrolidine) amides. Wallén EA; Christiaans JA; Jarho EM; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J J Med Chem; 2003 Oct; 46(21):4543-51. PubMed ID: 14521416 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide. Racys DT; Rea D; Fülöp V; Wills M Bioorg Med Chem; 2010 Jul; 18(13):4775-82. PubMed ID: 20627594 [TBL] [Abstract][Full Text] [Related]
7. Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. Venäläinen JI; Juvonen RO; Forsberg MM; Garcia-Horsman A; Poso A; Wallen EA; Gynther J; Männistö PT Biochem Pharmacol; 2002 Aug; 64(3):463-71. PubMed ID: 12147298 [TBL] [Abstract][Full Text] [Related]
8. 2(S)-(Cycloalk-1-enecarbonyl)-1-(4-phenyl-butanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4-phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitors. Jarho EM; Venäläinen JI; Poutiainen S; Leskinen H; Vepsäläinen J; Christiaans JA; Forsberg MM; Männistö PT; Wallén EA Bioorg Med Chem; 2007 Mar; 15(5):2024-31. PubMed ID: 17215128 [TBL] [Abstract][Full Text] [Related]
9. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP). Haffner CD; Diaz CJ; Miller AB; Reid RA; Madauss KP; Hassell A; Hanlon MH; Porter DJ; Becherer JD; Carter LH Bioorg Med Chem Lett; 2008 Aug; 18(15):4360-3. PubMed ID: 18606544 [TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of peptide-based prolyl oligopeptidase inhibitors--introduction of N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine as a lead in inhibitor design. Goossens F; Vanhoof G; De Meester I; Augustyns K; Borloo M; Tourwe D; Haemers A; Scharpé S Eur J Biochem; 1997 Nov; 250(1):177-83. PubMed ID: 9432007 [TBL] [Abstract][Full Text] [Related]
12. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. Jarho EM; Venäläinen JI; Huuskonen J; Christiaans JA; Garcia-Horsman JA; Forsberg MM; Järvinen T; Gynther J; Männistö PT; Wallén EA J Med Chem; 2004 Nov; 47(23):5605-7. PubMed ID: 15509157 [TBL] [Abstract][Full Text] [Related]
13. Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors. Tarragó T; Masdeu C; Gómez E; Isambert N; Lavilla R; Giralt E ChemMedChem; 2008 Oct; 3(10):1558-65. PubMed ID: 18792035 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel (123)I-labeled 4-(4-iodophenyl)butanoyl-L-prolyl-(2S)-pyrrolidines for imaging prolyl oligopeptidase in vivo. Kallinen A; Todorov B; Kallionpää R; Bäck S; Sarparanta M; Raki M; García-Horsman JA; Bergström KA; Wallén EA; Männistö PT; Airaksinen AJ Eur J Med Chem; 2014 May; 79():436-45. PubMed ID: 24763264 [TBL] [Abstract][Full Text] [Related]
15. Fluorescence resonance energy transfer (FRET) peptides and cycloretro-inverso peptides derived from bradykinin as substrates and inhibitors of prolyl oligopeptidase. Gorrão SS; Hemerly JP; Lima AR; Melo RL; Szeltner Z; Polgár L; Juliano MA; Juliano L Peptides; 2007 Nov; 28(11):2146-54. PubMed ID: 17904692 [TBL] [Abstract][Full Text] [Related]
17. Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution. Tsunemi M; Matsuura Y; Sakakibara S; Katsube Y Biochemistry; 1996 Sep; 35(36):11570-6. PubMed ID: 8794736 [TBL] [Abstract][Full Text] [Related]
18. Substrate- and pH-dependent contribution of oxyanion binding site to the catalysis of prolyl oligopeptidase, a paradigm of the serine oligopeptidase family. Szeltner Z; Renner V; Polgár L Protein Sci; 2000 Feb; 9(2):353-60. PubMed ID: 10716187 [TBL] [Abstract][Full Text] [Related]
19. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors. Babkova K; Korabecny J; Soukup O; Nepovimova E; Jun D; Kuca K Future Med Chem; 2017 Jun; 9(10):1015-1038. PubMed ID: 28632451 [TBL] [Abstract][Full Text] [Related]
20. Novel inhibitors of prolyl endopeptidase: effects of stereochemistry. Kolosko N; Bakker AV; Faraci WS; Nagel AA Drug Des Discov; 1994 Jan; 11(1):61-71. PubMed ID: 8068820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]